Markets

Health Care Sector Update for 11/14/2016: EBIO,CRBP,DVAX

A generic image of a pen and a calculator
Credit: Shutterstock photo

Top Health Care Stocks

JNJ -1.44%

PFE -1.21%

MRK -0.86%

ABT -1.97%

AMGN -1.09%

Health care stocks were moderately lower during Monday trade, with the NYSE Health Care Index falling about 0.8% while shares of health care companies in the S&P 500 were down about 0.4% as a group.

In company news, Eleven Biotherapeutics ( EBIO ) advanced Monday after the early-stage biotech company swung to a Q3 profit following a big jump in quarterly revenue compared with the same period last year.

The company earned $0.91 per diluted share during the three months ended Sept. 30, reversing a $0.50 per share net loss during the same quarter last year. Revenue jumped to $28.7 million during the quarter, improving on just $100,000 in revenue during the year-ago period because of a big spike in revenue from the company's license agreement with Roche. No analyst estimates were available for comparison.

EBIO shares were up more than 11% at $2.92 apiece, previously hitting a session high today at $3.23 a share.

In other sector news,

(+) CRBP, (+45.3%) Topline results indicate "clear signal of clinical benefit" of Resunab drug candidate in patients with systemic sclerosis during Phase II testing.

(-) DVAX, (-62.9%) FDA issues complete response letter to a biologics license application for Heplisav-B, effectively rejecting the prospective hepatitis B vaccine.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

DVAX CRBP

Other Topics

US Markets